Clinical bottom line
Exercise-induced anaphylaxis (EIA), including food-dependent exercise-induced anaphylaxis (FDEIA), is a rare but potentially life-threatening condition requiring prompt recognition and tailored management. Recent guidelines emphasize individualized avoidance strategies, patient education on trigger identification, and preparedness with emergency medications such as epinephrine auto-injectors. Advances in understanding cofactors and diagnostic approaches have improved clinical management, though challenges remain in predicting and preventing episodes. Multidisciplinary care and patient engagement are key to optimizing outcomes (Geller et al., 2020; Feldweg et al., 2017).
What the evidence shows
EIA is characterized by anaphylaxis triggered by physical exertion, sometimes in combination with cofactors like food ingestion, medications, or environmental factors. Geller et al. (2020) provide a comprehensive review of clinical management, highlighting the importance of detailed history to identify triggers and cofactors.
FDEIA is a well-recognized subtype where ingestion of specific foods prior to exercise precipitates anaphylaxis. Feldweg et al. (2017) outline diagnostic criteria and recommend avoidance of implicated foods before exercise alongside standard anaphylaxis precautions.
Japanese guidelines for food allergy (Ebisawa et al., 2020) incorporate recommendations for FDEIA, emphasizing patient education on timing of food intake relative to exercise and recognition of early symptoms.
Sánchez-Borges et al. (2020) discuss oral mite anaphylaxis as a related phenomenon, underscoring the complexity of allergen exposure in EIA.
Management includes avoidance of known triggers, modification of exercise intensity or timing, and readiness with epinephrine. Adjunctive therapies such as antihistamines may be used but do not replace emergency treatment.
Patient education on self-monitoring and emergency response is critical to reduce morbidity.
Caveats and uncertainty
Diagnosis can be challenging due to variability in symptom presentation and overlap with other exercise-related conditions.
Provocation testing is rarely performed due to safety concerns, limiting definitive diagnosis.
Predicting episodes remains difficult given multifactorial triggers and individual variability.
Evidence for pharmacologic prophylaxis beyond epinephrine is limited.
Long-term natural history and risk factors for recurrence require further study.
How this may change practice
Clinicians should maintain high suspicion for EIA and FDEIA in patients with exercise-related anaphylaxis symptoms.
Comprehensive assessment of cofactors and detailed patient history are essential.
Personalized management plans including trigger avoidance, exercise modification, and emergency preparedness should be developed.
Education on epinephrine auto-injector use and prompt treatment of symptoms must be prioritized.
Collaboration with allergy specialists can aid in diagnosis and optimization of care.
Ongoing research may refine diagnostic tools and preventive strategies.